Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio logo

About Gritstone bio Stock (NASDAQ:GRTS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.63
52-Week Range
N/A
Volume
61.02 million shs
Average Volume
7.01 million shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17
Consensus Rating
Moderate Buy

Company Overview

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

Gritstone Bio sets sale of assets through Bankruptcy Court
Gritstone Oncology Inc (GRTSQ)
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
Gritstone Oncology Pursues Restructuring Through Chapter 11
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
See More Headlines

GRTS Stock Analysis - Frequently Asked Questions

Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.12. The company had revenue of $0.92 million for the quarter, compared to analysts' expectations of $2.77 million. Gritstone bio had a negative trailing twelve-month return on equity of 328.51% and a negative net margin of 910.50%.

Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/13/2024
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.17
High Stock Price Target
$5.00
Low Stock Price Target
$0.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$138.49 million
Net Margins
-910.50%
Pretax Margin
-910.50%

Debt

Sales & Book Value

Annual Sales
$496 thousand
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
N/A

Miscellaneous

Free Float
111,837,000
Market Cap
$3.50 million
Optionable
Optionable
Beta
0.49
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:GRTS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners